ライフサイエンスコーパス: tumor resection

1 etastases and extends survival after primary tumor resection.

2 ng micrometastatic disease following primary tumor resection.

3 mize language deficits associated with brain-tumor resection.

4 initially cured by transsphenoidal pituitary tumor resection.

5 evaluated intracerebral CED of CB along with tumor resection.

6 lped to reduce the morbidity associated with tumor resection.

7 rse bone loss caused by trauma, disease, and tumor resection.

8 herapy including radiation, chemotherapy, or tumor resection.

9 70 RU per milliliter, which normalized after tumor resection.

10 ntensive care unit stay after craniotomy for tumor resection.

11 r growth, and minimal residual disease after tumor resection.

12 term survival depends critically on complete tumor resection.

13 e, trauma, infection, radiation necrosis, or tumor resection.

14 ke, and then on selected days after surgical tumor resection.

15 f CD3+ cells in the spleen within 24-48 h of tumor resection.

16 rostate cancer ensues after complete primary tumor resection.

17 ce metastatic relapse after primary prostate tumor resection.

18 moderately increased survival after primary tumor resection.

19 high local recurrence rate due to incomplete tumor resection.

20 Tumor resection.

21 ted this therapy several years after primary tumor resection.

22 me (<10 mm(3)) only possible by day 20 after tumor resection.

23 ed to assess factors associated with primary tumor resection.

24 here postoperative MRI suggested gross total tumor resection.

25 ively assessed tumor adhesion at the time of tumor resection.

26 tical imaging have improved the precision of tumor resection.

27 23,004 (60.9%) underwent palliative primary tumor resection.

28 IV CRC, 43,273 (67.4%) had undergone primary tumor resection.

29 ronavigated tissue-sampling procedure during tumor resection.

30 ted residual tumor after presumably complete tumor resection.

31 assessing surgical margins for maximal safe tumor resection.

32 and 74% had full recovery after therapy and tumor resection.

33 s administration of contrast material before tumor resection.

34 y express tumor markers and are decreased by tumor resection.

35 m five research subjects who underwent brain tumor resection.

36 tients with pancreatic cancer after complete tumor resection.

37 f treatment appear to be superior to upfront tumor resection.

38 d during the perioperative period of primary tumor resection.

39 t tissue, resulting in improved precision of tumor resection.

40 ally invasive surgery, will influence future tumor resections.

41 Twenty-four patients had tumor resection (19 Whipple, four total pancreatectomy,

42 ending on whether they were to be treated by tumor resection, 5 weeks of CS-682 chemotherapy at 40-60

43 ) and among patients treated with or without tumor resection (all P < .001).

44 luding checkpoint immunotherapies, and early tumor resection and (neo)adjuvant chemotherapy fails to

45 om 232 patients (T3-4, N0, M0) with complete tumor resection and a median follow-up of 97 months was

46 In three cases, localized tumor resection and a variety of reconstructive techniqu

47 A combination of repeat tumor resection and adjuvant chemotherapy resulted in pr

48 metastatic disease many years after primary tumor resection and adjuvant therapy seems to arise from

49 followed by vascular reconstruction, ex vivo tumor resection and autotransplantation of excised organ

50 mg daily, started after potentially curative tumor resection and chemotherapy or radiotherapy as indi

51 oup of tumor-bearing animals by serial kill, tumor resection and counting of radioactivity in a gamma

52 Tumor resection and immunotherapy resulted in improvemen

53 Rates of primary tumor resection and median relative survival were calcul

54 igational systems, to evaluate the extent of tumor resection and modify surgery if necessary, to guid

55 e patients and 1 male patient underwent iris tumor resection and presented to our service with suspic

56 Clinical use of the GAINS to guide tumor resection and sentinel lymph node mapping promises

57 December 31, 2010, who had undergone primary tumor resection and those who had not.

58 patients (29.0%) did not require additional tumor resection and were analyzed as a separate group.

59 euroblastoma resection, 170 (55.2%) a kidney tumor resection, and 123 (39.9%) an operation to treat b

60 aging allowed for guidance of intraoperative tumor resection, and a histological correlation validate

61 ic evaluation at restaging), margin-negative tumor resection, and overall survival were evaluated usi

62 trated advanced diagnostic ability, enhanced tumor resection, and reduced tumor recurrence.

63 ho required re-irradiation, vitrectomies, or tumor resections; and those whose treatment was performe

64 t for all neurosurgical patients after brain tumor resection are not clear.

65 Although biopsies and tumor resection are prognostically beneficial for gliobl

66 for, symptomatic disease, with less than 50% tumor resection at diagnosis, or with unresectable progr

67 Five of 12 patients (42%) had a complete tumor resection at diagnosis.

68 ere found to be predictive for the extent of tumor resection at first (P < .001) and best (P < .001)

69 ften represents the only barrier to complete tumor resection at the time of pancreaticoduodenectomy.

70 eriments and observations, including primary tumor resection at week 9 and release from the treatment

71 cellular carcinoma who had undergone radical tumor resection between 1999 and 2003.

72 ents with stage IV CRC had undergone primary tumor resection but, beginning in 2001, a trend toward f

73 n pediatric HCC is more likely when complete tumor resection can be achieved.

74 Aggressive tumor resection can lead to the need for extensive recon

75 chimeric 81C6 administered directly into the tumor resection cavities of brain tumor patients.

76 stem cells increased their retention in the tumor resection cavity, permitted tumor-selective migrat

77 1, 2011, with complete data sets for RT, CT, tumor resection, Charlson-Deyo comorbidity scores, age,

78 The annual rate of primary tumor resection decreased from 74.5% in 1988 to 57.4% in

79 ibody titers); two of three patients without tumor resection died of neurological deterioration.

80 nty-three of 46 patients (50%) who underwent tumor resection died.

81 gnificant predictive variables of incomplete tumor resection: diffuse tumor margin on T2-weighted MR

82 The association between the extent of tumor resection (EOR) and outcome remains undefined, not

83 Tumor resection followed a minimum of three cycles.

84 All patients underwent tumor resection followed by a single intraparenchymal in

85 hemotherapeutic and biologic agents, primary tumor resection for patients with stage IV colorectal ca

86 n of language areas in a patient after brain tumor resection, from strong left-sided to symmetrical l

87 e to oncological interventions, particularly tumor resection, go hand in hand with cognitive outcome.

88 hen drug treatment was combined with primary tumor resection, greater than 60% of the mice were cured

89 (group 1, 60 patients) or SDRT combined with tumor resection (group 2, 18 patients).

90 he development of an intraoperative tool for tumor resection guidance with the aim of enabling oncolo

91 ypoplasia and the other with posterior fossa tumor resection-had markedly improved corneal sensation

92 congenital anomalies, infections, trauma, or tumor resection, how orofacial stem/progenitor cells con

93 reduced DDX5 exhibited poor prognosis after tumor resection, identifying DDX5 as an important player

94 with recurrent high-grade gliomas underwent tumor resection, implantation of an intracavitary reserv

95 he main variables associated with incomplete tumor resection in 101 patients were identified by using

96 evaluated at initial diagnosis), leading to tumor resection in all cases.

97 ld MRI significantly increased the extent of tumor resection in this subgroup of malignant gliomas lo

98 However, maximization of the extent of tumor resection is hampered by difficulty in intraoperat

99 Primary chemotherapy with delayed tumor resection is increasingly advocated for patients w

100 In carefully selected patients, tumor resection is often possible; however, the perioper

101 Although early after tumor cell inoculation tumor resection leads to the development of immunity, th

102 feasibility for detecting residual cancer on tumor resection margins, using a genetically engineered

103 w for enhanced intraoperative delineation of tumor resection margins.

104 However, primary tumor resection may still be overused, and current treat

105 Mechanical stimuli during tumor resection may therefore negatively impact patient

106 Despite early tumor resection, mice died from locally recurring and di

107 l analysis suggested that SDRT with combined tumor resection might be associated with increased tumor

108 Our results suggested that tumor resection not only led to the reversal of immune s

109 dy evaluated the impact of extent of primary tumor resection on local progression and survival and as

110 astatic neuroblastoma, the impact of primary tumor resection on outcome is a matter of medical debate

111 t because no studies have shown an effect of tumor resection on survival.

112 tigate the effect of drug administration and tumor resection on these quantities and predict the surv

113 tential curative options for this malignancy-tumor resection or organ transplantation.

114 n 40 years of age and had undergone subtotal tumor resection or who were 40 years of age or older, pr

115 cerous lesions, to delineate the margins for tumor resection, or as a feedback mechanism to assess re

116 tend through the jaws as a result of trauma, tumor resection, or congenital defects.

117 nts were 158 consecutive postoperative brain tumor resection patients admitted to a neurocritical car

118 Tumor resection performed at this complex region poses a

119 re is a need to image excised tissues during tumor-resection procedures in order to identify residual

120 adjuvant administration of gemcitabine after tumor resection prolonged survival.

121 Primary tumor resection (PTR) is recommended for patients with u

122 Complete surgical tumor resection (R0) for treatment of intrahepatic chola

123 a significant change in trend in the primary tumor resection rate had occurred.

124 Despite the decreasing primary tumor resection rate, patient survival rates improved.

125 Difference in primary tumor resection rates over time.

126 ckade administered immediately after primary tumor resection reduces metastatic relapse from 97.4 to

127 Tumor resection remains the only curative treatment but

128 efficacy of Neuregen for treatment of brain tumor resections remains to be determined.

129 Twenty-seven patients underwent tumor resection (resectability rate 71%), of which 26 in

130 al MPS and a trend toward increased MPB, and tumor resection reverses these derangements.

131 In patients with macroscopically complete tumor resection, RHT in addition to chemotherapy resulte

132 eatic cancer regardless of disease stage and tumor resection status (overweight patients: hazard rati

133 s permits larger instruments and may improve tumor resection, the outcome is determined by tumor char

134 urrent cases, the mean interval from initial tumor resection to detection of recurrence was 58 months

135 Adjuvant therapies were given after primary tumor resections to treat postsurgical regrowths and dis

136 e during the perioperative period of primary tumor resection, to confer protection against B16 melano

137 estigate the changes in ctDNA after surgical tumor resection, tumor and blood samples obtained before

138 and another following large posterior fossa tumor resection-underwent corneal sensory reconstruction

139 Local tumor resection using lamellar sclerouvectomy is mainly

140 patients with and without palliative primary tumor resection using risk-adjusted Cox proportional haz

141 5-year disease-specific survival rate after tumor resection was 65%.

142 Complete tumor resection was achieved in 34 patients (40%), inclu

143 lorectal cancer patients, palliative primary tumor resection was associated with improved overall and

144 Tumor resection was attempted.

145 ltivariate analyses revealed that incomplete tumor resection was due to tumor involvement of the cort

146 8 patients with stage III or IV disease, and tumor resection was possible in two (10%) of the remaini

147 Finally, the extent of tumor resections was correlated with local control rate

148 inning in 2001, a trend toward fewer primary tumor resections was seen.

149 Factors associated with primary tumor resection were age younger than 50 years, female s

150 t the tumor core and invasive rim of a human tumor resection were compared.

151 erred for functional MR imaging for possible tumor resection were prospectively evaluated.

152 es (SNs) and non-SNs obtained during primary tumor resection were sectioned at multiple levels and st

153 Seven samples of tumor resections were excluded from the study because th

154 T before and after chemotherapy, followed by tumor resection, were retrospectively reviewed.

155 substantial recovery after immunotherapy and tumor resection when appropriate.

156 enic effects on the NMDAR, immunotherapy and tumor resection, when appropriate, are often effective.

157 al margins occur in a significant portion of tumor resections, which is directly correlated with a po

158 n goal of brain tumor surgery is to maximize tumor resection while preserving brain function.

159 The likelihood of complete tumor resection with a negative microscopic margin and c

160 To study language function after brain-tumor resection with language mapping, we examined 250 c

161 Prior tumor resection with lateral wall osteotomy, delay in IA

162 We achieved a complete tumor resection with negative margins in all cases.

163 compared with 51% in patients with complete tumor resection with residual tumor (P =.03).

164 ong patients with normal CRP levels, radical tumor resection within multimodality therapy was associa

165 eved after radical prostatectomy is complete tumor resection without recurrence and full recovery of

166 Eighteen of 27 patients (63%) with complete tumor resection (without LTX) and 20 of 34 patients (59%